Are your kidneys Ok? Detect early to protect kidney health

Early identification of kidney disease can protect kidney health, prevent kidney disease progression and related complications, reduce cardiovascular disease risk, and decrease mortality. We must ask “Are your kidneys ok?” using serum creatinine to estimate kidney function and urine albumin to assess for kidney and endothelial damage. Evaluation for causes and risk factors for chronic kidney disease (CKD) includes testing for diabetes and measurement of blood pressure and body mass index. This World Kidney Day we assert that case-finding in high-risk populations, or even population level screening, can decrease the burden of kidney disease globally. Early-stage CKD is asymptomatic and simple to test for, and recent paradigm shifting CKD treatments such as sodium glucose co-transporter-2 inhibitors dramatically improve outcomes and favor the cost-benefit analysis for screening or case-finding programs. Despite this, numerous barriers exist, including resource allocation, health care funding, health care infrastructure, and health care professional and population awareness of kidney disease. Coordinated efforts by major kidney nongovernmental organizations to prioritize the kidney health agenda for governments and aligning early detection efforts with other current programs will maximize efficiencies.

1. Ndumele CE, Neeland IJ, Tuttle KR, et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association. Circulation. 2023;148:1636–1664.

2. Luyckx VA, Tuttle KR, Abdellatif D, et al. World Kidney Day Joint Steering Committee. Mind the gap in kidney care: translating what we know into what we do. Kidney Int. 2024;105:406– 417.

3. Stevens PE, Ahmed SB, Carrero JJ, et al. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105:S117–S314.

4. Guha C, Lopez-Vargas P, Ju A, et al, PAVE-CKD Work-shop Investigators. Patient needs and priorities for patient navigator programmes in chronic kidney disease: a workshop report. BMJ Open. 2020;10: e040617.

5. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395:709–733.

6. Cojuc-Konigsberg G, Guijosa A, Moscona-Nissan A, et al. Representation of low- and middle-income countries in CKD drug trials: a systematic review. Am J Kidney Dis. 2025;85:55–66. e1.

7. Hsiao LL, Shah KM, Liew A, et al, World Kidney Day Joint Steering Committee. Kidney health for all: preparedness for the unexpected in supporting the vulnerable. Kidney Int. 2023;103:436–443.

8. Francis A, Harhay MN, Ong ACM, et al. Chronic kidney disease and the global public health agenda: an international consensus. Nat Rev Nephrol. 2024;20: 473–485.

9. Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and all-cause and causespecific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. Lancet. 2018;392:2052–2090.

10. Viggiano D, Wagner CA, Martino G, et al. Mechanisms of cognitive dysfunction in CKD. Nat Rev Nephrol. 2020;16:452– 469.

11. Chen K, Didsbury M, van Zwieten A, et al. Neurocognitive and educational outcomes in children and adolescents with CKD: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2018;13:387–397.

12. Francis A, Didsbury MS, van Zwieten A, et al. Quality of life of children and adolescents with chronic kidney disease: a cross-sectional study. Arch Dis Child. 2019;104:134–140.

13. United States Renal Data System. 2023 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2023.

14. Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015;385:1975–1982.

15. Bello AK, Levin A, Tonelli M, et al. Assessment of global kidney health care status. JAMA. 2017;317:1864–1881.

16. Ortiz A, Wanner C, Gansevoort R, ERA Council. Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the Council of the European Renal Association. Nephrol Dial Transplant. 2023;38:527–531.

17. Johnson RJ, Wesseling C, Newman LS. Chronic kidney disease of unknown cause in agricultural communities. N Engl J Med. 2019;380:1843–1852.

18. McCulloch M, Luyckx VA, Cullis B, et al. Challenges of access to kidney care for children in low-resource settings. Nat Rev Nephrol. 2021;17:33–45.

19. Stanifer JW, Muiru A, Jafar TH, Patel UD. Chronic kidney disease in low- and middle-income countries. Nephrol Dial Transplant. 2016;31:868–874.

20. Levey AS, Schoolwerth AC, Burrows NR, et al. Comprehensive public health strategies for preventing the development, progression, and complications of CKD: report of an expert panel convened by the Centers for Disease Control and Prevention. Am J Kidney Dis. 2009;53:522–535.

21. International Society of Nephrology. World Kidney Day 2025. Accessed January 11, 2025. https://www.worldkidneyday.org/about-kidney-health/

22. Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life’s Essential 8: updating and enhancing the American Heart Association’s Construct of Cardiovascular Health: a presidential advisory from the American Heart Association. Circulation. 2022;146:e18– e43.

23. Bello AK, Okpechi IG, Levin A, et al, ISN-GKHA Group. An update on the global disparities in kidney disease burden and care across world countries and regions. Lancet Glob Health. 2024;12:e382–e395.

24. Ferre S, Storfer-Isser A, Kinderknecht K, et al. Fulfillment and validity of the kidney health evaluation measure for people with diabetes. Mayo Clin Proc Innov Qual Outcomes. 2023;7:382–391.

25. Alfego D, Ennis J, Gillespie B, et al. Chronic kidney disease testing among at-risk adults in the U.S. remains low: real-world evidence from a national laboratory database. Diabetes Care. 2021;44:2025– 2032.

26. Stempniewicz N, Vassalotti JA, Cuddeback JK, et al. Chronic kidney disease testing among primary care patients with type 2 diabetes across 24 U.S. health care organizations. Diabetes Care. 2021;44:2000–2009.

27. Kushner PR, DeMeis J, Stevens P, et al. Patient and clinician perspectives: to create a better future for chronic kidney disease, we need to talk about our kidneys. Adv Ther. 2024;41:1318–1324.

28. Farrell DR, Vassalotti JA. Screening, identifying, and treating chronic kidney disease: why, who, when, how, and what? BMC Nephrol. 2024;25:34.

29. Tuttle KR. CKD screening for better kidney health: Why? Who? How? When? Nephrol Dial Transplant. 2024;39:1537– 1539.

30. Shlipak MG, Tummalapalli SL, Boulware LE, et al. The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2021;99:34–47.

31. Tummalapalli SL, Shlipak MG, Damster S, et al. Availability and affordability of kidney health laboratory tests around the globe. Am J Nephrol. 2020;51:959–965.

32. Seegmiller JC, Bachmann LM. Urine albumin measurements in clinical diagnostics. Clin Chem. 2024;70:382–391.

33. van Mil D, Kieneker LM, Heerspink HJL, Gansevoort RT. Screening for chronic kidney disease: change of perspective and novel developments. Curr Opin Nephrol Hypertens. 2024;33:583–592.

34. Sacks DB, Arnold M, Bakris GL, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2023;69(8):808– 868.

35. Tonelli M, Dickinson JA. Early detection of CKD: implications for low-income, middle-income, and highincome countries. J Am Soc Nephrol. 2020;31:1931–1940.

36. Moreno JA, Martin-Cleary C, Gutierrez E, et al. Haematuria: the forgotten CKD factor? Nephrol Dial Transplant. 2012;27(1):28–34.

37. Franceschini N, Feldman DL, Berg JS, et al. Advancing genetic testing in kidney diseases: report from a National Kidney Foundation Working Group. Am J Kidney Dis. 2024;84:751–766.

38. Mjøen G, Hallan S, Hartmann A, et al. Long-term risks for kidney donors. Kidney Int. 2014;86:162–167.

39. Francis A, Abdul Hafidz MI, Ekrikpo UE, et al. Barriers to accessing essential medicines for kidney disease in low- and lower middle-income countries. Kidney Int. 2022;102:969–973.

40. Nuffield Department of Population Health Renal Studies Group. SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400(10365):1788–1801.

41. Vart P, Vaduganathan M, Jongs N, et al. Estimated life-time benefit of combined RAAS and SGLT2 inhibitor therapy in patients with albuminuric CKD without diabetes. Clin J Am Soc Nephrol. 2022;17:1754–1762.

42. Vanholder R, Annemans L, Brown E, et al.; European Kidney Health Alliance. Reducing the costs of chronic kidney disease while delivering quality health care: a call to action. Nat Rev Nephrol. 2017;13:393–409.

43. Berman-Parks N, Berman-Parks I, Gómez-Ruíz IA, et al. Combining patient care and environmental protection: a pilot program recycling polyvinyl chloride from automated peritoneal dialysis waste. Kidney Int Rep. 2024;9:1908–1911.

44. Essue BM, Laba M, Knaul F, et al. Economic burden of chronic ill health and injuries for households in lowand middle-income countries. In: Jamison DT, Gelband H, Horton S, Jha P, Laxminarayan R, Mock CN, et al., eds. Disease Control Priorities: Improving Health and Reducing Poverty. The International Bank for Reconstruction and Development; 2018 and The World Bank; 2017.

45. Yeo SC, Wang H, Ang YG, et al. Cost-effectiveness of screening for chronic kidney disease in the general adult population: a systematic review. Clin Kidney J. 2024;17:sfad137.

46. Cusick MM, Tisdale RL, Chertow GM, et al. Population-wide screening for chronic kidney disease : a cost-effectiveness analysis. Ann Intern Med. 2023;176:788–797.

47. Yadla M, John P, Fong VK, Anandh U. Ethical issues related to early screening programs in low resource settings. Kidney Int Rep. 2024;9:2315–2319.

48. Szczech LA, Stewart RC, Su HL, et al. Primary care detection of chronic kidney disease in adults with type-2 diabetes: the ADD-CKD Study (Awareness, Detection and Drug Therapy in Type 2 Diabetes and Chronic Kidney Disease). PLoS One. 2014;9:e110535.

49. Vassalotti JA, Centor R, Turner BJ, et al. National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Practical approach to detection and management of chronic kidney disease for the primary care clinician. Am J Med. 2016;129(2):153–162.e7.

50. Thavarajah S, Knicely DH, Choi MJ. CKD for primary care practitioners: can we cut to the chase without too many shortcuts? Am J Kidney Dis. 2016;67:826– 829.

51. Vassalotti JA, Boucree SC. Integrating CKD Into US primary care: bridging the knowledge and implementation gaps. Kidney Int Rep. 2022;7:389–396.

52. Luyckx VA, Moosa MR. Priority setting as an ethical imperative in managing global dialysis access and improving kidney care. Semin Nephrol. 2021;41: 230–241.

53. US Centers for Disease Control and Prevention. Chronic kidney disease in the United States 2023. Accessed January 11, 2025. https://www.cdc.gov/kidney-disease/php/data-research/index.html

54. Dattani S, Spooner F, Ritchie H, Roser M. Causes of death. 2023. Accessed January 11, 2025. https://ourworldindata.org/causes-of-death

55. Boulware LE, Carson KA, Troll MU, et al. Perceived susceptibility to chronic kidney disease among highrisk patients seen in primary care practices. J Gen Intern Med. 2009;24:1123–1129.

56. National Kidney Foundation. Kidney quiz 2024. Accessed January 11, 2025. https://www.kidney.org/kidney-quiz/

57. Tuot DS, Crowley ST, Katz LA, et al. Usability testing of the kidney score platform to enhance communication about kidney disease in primary care settings: qualitative think-aloud study. JMIR Form Res. 2022;6: e40001.